Exendin pharmaceutical compositions
DCFirst Claim
Patent Images
1. A pharmaceutical composition comprising an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient;
- a pharmaceutically acceptable buffer;
a pharmaceutically acceptable isotonicity agent; and
a pharmaceutically acceptable carrier.
5 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
-
Citations
32 Claims
-
1. A pharmaceutical composition comprising an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient;
- a pharmaceutically acceptable buffer;
a pharmaceutically acceptable isotonicity agent; and
a pharmaceutically acceptable carrier. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
- a pharmaceutically acceptable buffer;
-
10. A pharmaceutical composition comprising an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient;
- a pharmaceutically acceptable isotonicity agent selected from the group consisting of sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, a polyol, and a combination of two or more thereof; and
a pharmaceutically acceptable buffer. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- a pharmaceutically acceptable isotonicity agent selected from the group consisting of sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, a polyol, and a combination of two or more thereof; and
-
22. A pharmaceutical composition comprising (i) an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient;
- (ii) mannitol, sorbitol, or a combination thereof; and
(iii) an acetate buffer. - View Dependent Claims (23, 24, 25, 26, 27, 28)
- (ii) mannitol, sorbitol, or a combination thereof; and
-
29. A subcutaneously injectable pharmaceutical composition comprising (i) an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient;
- (ii) mannitol, sorbitol, or a combination thereof;
(iii) an acetate buffer; and
(iv) a pharmaceutically acceptable aqueous carrier. - View Dependent Claims (30, 31, 32)
- (ii) mannitol, sorbitol, or a combination thereof;
Specification